BSE Live
Feb 20, 16:01Prev. Close
869.05
Open Price
869.35
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Feb 20, 15:57Prev. Close
870.20
Open Price
867.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
| Cash Flow of Strides Pharma Science (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 3,675.03 | -116.94 | -286.20 | -652.51 | 289.38 | |
| Net CashFlow From Operating Activities | 684.37 | 701.07 | 44.41 | -257.82 | 481.44 | |
| Net Cash Used In Investing Activities | -89.69 | -150.25 | 302.47 | -118.73 | -520.82 | |
| Net Cash Used From Financing Activities | -642.58 | -693.32 | -213.92 | 421.32 | -15.80 | |
| Foreign Exchange Gains / Losses | -0.54 | 0.16 | 0.15 | 0.13 | -1.22 | |
| Adjustments On Amalgamation Merger Demerger Others | -0.02 | -0.14 | -0.34 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | -48.46 | -142.48 | 132.77 | 44.90 | -56.40 | |
| Cash And Cash Equivalents Begin of Year | 161.02 | 303.50 | 170.73 | 125.83 | 182.23 | |
| Cash And Cash Equivalents End Of Year | 112.56 | 161.02 | 303.50 | 170.73 | 125.83 |
03.02.2026
Strides Pharma Consolidated December 2025 Net Sales at Rs 1,194.65 crore, up 3.55% Y-o-Y
03.02.2026
Strides Pharma Standalone December 2025 Net Sales at Rs 553.63 crore, up 0.49% Y-o-Y
26.12.2025
10.11.2025
Strides Pharma Standalone September 2025 Net Sales at Rs 522.15 crore, down 14.4% Y-o-Y
03.02.2026
Strides Pharma Consolidated December 2025 Net Sales at Rs 1,194.65 crore, up 3.55% Y-o-Y
03.02.2026
Strides Pharma Standalone December 2025 Net Sales at Rs 553.63 crore, up 0.49% Y-o-Y
10.11.2025
Strides Pharma Standalone September 2025 Net Sales at Rs 522.15 crore, down 14.4% Y-o-Y
31.10.2025
Strides Pharma Consolidated September 2025 Net Sales at Rs 1,220.83 crore, up 1.64% Y-o-Y
12.04.2021
Strides Pharma Science Q4 PAT may dip 488.7% YoY to Rs. 72.3 cr: Sharekhan
12.04.2018
Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key
18.01.2018
Pharma Q3 earnings preview - cos brace for challenging quarter, US and India sales hold key
17.08.2016